array(0) {
array(0) {
End Google Tag Manager
London Private Hospital, The Harley Street Clinic

Latest News

array(0) {

July 26th 2016

The Harley Street Clinic launches Dorsal Root Ganglion (DRG) Stimulation

Professor Keyoumars Ashkan on behalf of the London Neurosurgery Partnership is delighted to offer the Dorsal Root Ganglion (DRG) Stimulation to our patients at The Harley Street Clinic, as a part of his neuromodulation practice for intractable pain management.

Spinal cord stimulation (SCS) has been used successfully to treat patients with chronic neuropathic pain for over 30 years and has National Institute for Health and Care Excellence (NICE) approval.1  It is very effective for certain pain conditions, but there are some pain locations that can be difficult to target with conventional SCS or the stimulation can be too widespread and this in itself can be unpleasant for patients with focal pain to deal with.

There is now a new form of spinal cord stimulation available that targets the dorsal root ganglion (DRG) and this is particularly effective for focal pain or distal extremity pain. This form of treatment is the most effective in treating the following conditions:

  • Foot or hand pain (CRPS or post-surgical neuropathic pain),
  • Groin pain
  • Post-surgical scar pain (e.g. after hernia repair)
  • Neuropathic knee pain (e.g after knee surgery)
  • Diabetic neuropathy
  • Thoracic pain post surgery
  • Post-amputation pain.

There is now Level 1 evidence for DRG stimulation from the ACCURATE Study. This is the largest randomized, controlled neuromodulation trial in CRPS and peripheral causalgia patients and it was conducted to provide evidence of safety and efficacy for market approval in the United States.

Long-term, 12-month data from the ACCURATE study showed DRG stimulation offered patients:

  • Sustained and superior pain relief: After 12 months, the ACCURATE study demonstrated a statistically significantly number of patients receiving DRG stimulation achieved meaningful pain relief and greater treatment success when compared to patients receiving traditional SCS (74.2 % vs. 53 %)
  • Improved therapeutic targeting: Nearly all patients receiving DRG stimulation reported better stimulation targeting in their area of pain without extraneous paresthesia than patients receiving traditional SCS (94.5 % vs. 61.2 %)
  • Reduced paresthesia: After 12 months, more than a third of patients who received DRG stimulation were experiencing greater than 80 % pain relief with no paresthesia.

For further details or to make an appointment please contact The London Neurosurgery Partnership on 020 7034 8707.

1. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. NICE technology appraisal guidance 159, October 2008